M
MCK
MCKReviewed6 segments tracked|8 years of data|Annual (10-K)
Total Revenue
$402.4B12.4%
FY2026
Operating Segments
6Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%North American Pharmaceutical Segment
Segment Shift
North American Pharmaceutical Segment has grown from 0.0% to 83.7% of total revenue since FY2019, with 0.0% operating margins. Meanwhile, Oncology And Multispecialty Segment is the fastest growing at +31.4% YoY.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2026
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| North American Pharmaceutical Segment | $336.7B | $0 | 0.0% | 83.7% | +10.6% |
| Oncology And Multispecialty Segment | $48.4B | $0 | 0.0% | 12.0% | +31.4% |
| Medical Surgical Solutions Segment | $11.5B | $0 | 0.0% | 2.9% | +1.1% |
| Prescription Technology Solutions Segment | $5.8B | $0 | 0.0% | 1.4% | +11.3% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free